Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anti-CD19-CAR is currently clinically available as one of the therapeutic modalities for refractory acute B-cell-typed lymphoblastic leukemia (B-ALL) patients.
|
30539476 |
2019 |
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Individual Patient Data Meta-Analysis from 16 Trials for Safety Factors in Cytokine Release Syndrome After CAR-T Therapy in Patients with Non-Hodgkin Lymphoma (NHL) and Acute Lymphoblastic Leukemia.
|
31428935 |
2019 |
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recently, adoptive immunotherapy, particularly chimeric antigen receptor T (CAR-T) cell therapy demonstrated promise for improving the survival of acute lymphoblastic leukemia with minimum toxicity.
|
30651858 |
2019 |
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
|
30120708 |
2018 |
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The European Medicines Agency (EMA) has approved 3 recombinant viral vector products: Glybera (UniQure, Amsterdam, The Netherlands), an rAAV vector for lipoprotein lipase deficiency; Strimvelis (Glaxo Smith-Kline, Brentford, United Kingdom), an <i>ex vivo</i> gammaretrovirus-based therapy for patients with adenosine deaminase-deficient severe combined immune deficiency (ADA-SCID); and Kymriah (Novartis, Basel, Switzerland), an <i>ex vivo</i> lentivirus-based therapy to engineer autologous chimeric antigen-receptor T (CAR-T) cells targeting CD19-positive cells in acute lymphoblastic leukemia.
|
31282760 |
2018 |
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Chimeric antigen receptor-engineered T (CAR-T) cells have extraordinary effect in treating lymphoblastic leukemia.
|
29716633 |
2018 |
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD19 targeted CAR-T therapy versus chemotherapy in re-induction treatment of refractory/relapsed acute lymphoblastic leukemia: results of a case-controlled study.
|
29417201 |
2018 |
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
FCM was performed on samples from 9 patients with B-ALL treated with CAR-T.
|
28888074 |
2018 |
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A pediatric patient diagnosed initially with B-lymphoblastic leukemia (B-ALL) relapsed with lineage switch to acute myeloid leukemia (AML) after chimeric antigen receptor T-cell (CAR-T) therapy and hematopoietic stem cell transplant.
|
29797659 |
2018 |
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We will review the data to date regarding anti-CD19 CAR T-cell therapy for acute lymphoblastic leukemia, non-Hodgkin lymphomas, and chronic lymphocytic leukemia.
|
28988742 |
2017 |
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anti-CD19 chimeric antigen receptor-modified T (CAR-T-19) cells have emerged as a powerful targeted immunotherapy for B-cell lineage acute lymphoblastic leukemia with a remarkable clinical response in recent trials.
|
27009300 |
2016 |
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CAR-T treatment has emerged as a promising approach for patients with hematological malignancies, and there are several works reporting clinical trials of the use of CAR-modified T-cells in acute lymphoblastic leukemia, chronic lymphoblastic leukemia, multiple myeloma, lymphoma, and in acute myeloid leukemia by targeting different antigens.
|
27865176 |
2016 |